Description
A cell-permeable LXR inverse agonist that induces LXR-corepressor interaction at nanomolar concentrations; disrupts the Warburg effect in cancer cells in culture and in vivo, suppressing the expression of glycolytic and lipogenic genes and reducing glycolytic metabolites and lipid production
Formal name: N-[2-(3-bromophenyl)ethyl]-2,4,6-trimethyl-N-[[3’-(methylsulfonyl)[1,1’-biphenyl]-4-yl]methyl]-benzenesulfonamide
Synonyms:
Molecular weight: 626.6
CAS: 1613028-81-1
Purity: ≥95%
Formulation: A crystalline solid
Product Type|Biochemicals|Receptor Pharmacology|Inverse Agonists||Research Area|Cancer|Cell Death|Apoptosis||Research Area|Cancer|Metabolism||Research Area|Endocrinology & Metabolism|Carbohydrate Metabolism||Research Area|Endocrinology & Metabolism|Hormones & Receptors|FXRs & LXRs||Research Area|Epigenetics, Transcription, & Translation|Transcription Factors